Günther Stockhammer

Author PubWeight™ 12.49^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma.	Neurology	2014	2.02
2	[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.	Neuro Oncol	2013	1.30
3	ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.	Neuroradiology	2010	1.20
4	A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).	Neuro Oncol	2013	1.01
5	RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study.	BMC Cancer	2009	0.87
6	The end-of-life phase of high-grade glioma patients: a systematic review.	Support Care Cancer	2013	0.87
7	In vivo release of vascular endothelial growth factor from colorectal carcinomas.	Oncology	2002	0.86
8	Response of recurrent high-grade glioma to treatment with (90)Y-DOTATOC.	J Nucl Med	2010	0.83
9	Multimodality cranial image fusion using external markers applied via a vacuum mouthpiece and a case report.	Strahlenther Onkol	2003	0.81
10	Galanin and galanin receptors in human gliomas.	Acta Neuropathol	2003	0.79
11	Response to "reply to [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al.	Neuro Oncol	2013	0.78
12	FACS analysis-a new and accurate tool in the diagnosis of lymphoma in the cerebrospinal fluid.	Clin Chim Acta	2002	0.77
13	Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.	Wien Klin Wochenschr	2006	0.76
14	Evoked potentials in a case of progressive multifocal leukoencephalopathy.	J Neurol	2003	0.75